Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)’s share price traded up 7.9% during mid-day trading on Tuesday . The company traded as high as $1.39 and last traded at $1.36. 838,531 shares were traded during trading, an increase of 30% from the average session volume of 645,946 shares. The stock had previously closed at $1.26.
A number of equities analysts have issued reports on the stock. ValuEngine lowered shares of Aralez Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Chardan Capital reduced their price target on shares of Aralez Pharmaceuticals from $5.50 to $4.00 and set a “buy” rating for the company in a research report on Thursday, August 10th.
The stock’s market capitalization is $90.91 million. The firm’s 50-day moving average is $1.17 and its 200-day moving average is $1.65.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.01). Aralez Pharmaceuticals had a negative return on equity of 90.17% and a negative net margin of 122.35%. The company had revenue of $27.62 million for the quarter, compared to analyst estimates of $21.37 million. During the same period in the prior year, the business earned ($0.27) earnings per share. Aralez Pharmaceuticals’s revenue for the quarter was up 119.6% compared to the same quarter last year. On average, equities research analysts anticipate that Aralez Pharmaceuticals Inc. will post ($1.62) earnings per share for the current year.
In related news, Director Arthur S. Kirsch purchased 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The stock was purchased at an average cost of $1.17 per share, with a total value of $58,500.00. Following the completion of the acquisition, the director now directly owns 206,609 shares in the company, valued at $241,732.53. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 6.70% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of ARLZ. Broadfin Capital LLC lifted its holdings in shares of Aralez Pharmaceuticals by 8.3% during the first quarter. Broadfin Capital LLC now owns 5,191,590 shares of the company’s stock worth $11,110,000 after purchasing an additional 400,000 shares during the period. Elk Creek Partners LLC lifted its holdings in shares of Aralez Pharmaceuticals by 13.3% during the first quarter. Elk Creek Partners LLC now owns 2,488,475 shares of the company’s stock worth $5,325,000 after purchasing an additional 292,420 shares during the period. GSA Capital Partners LLP lifted its holdings in shares of Aralez Pharmaceuticals by 88.5% during the second quarter. GSA Capital Partners LLP now owns 541,795 shares of the company’s stock worth $731,000 after purchasing an additional 254,400 shares during the period. Intrinsic Edge Capital Management LLC acquired a new stake in shares of Aralez Pharmaceuticals during the second quarter worth $270,000. Finally, KCG Holdings Inc. acquired a new stake in shares of Aralez Pharmaceuticals during the first quarter worth $310,000. 23.90% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Aralez Pharmaceuticals Inc. (ARLZ) Trading 7.9% Higher” was first published by Stock Observer and is the property of of Stock Observer. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.thestockobserver.com/2017/09/12/aralez-pharmaceuticals-inc-arlz-trading-7-9-higher.html.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.